Seres Therapeutics, Inc.
MCRB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001609809
In the last 90 days, Seres Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 35 institutions reported holding it in 13F filings for Q2 2026, worth $17.9M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Seres Therapeutics, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 103 | 99 | −4 |
| Shares | 89.5M | 85.8M | −3.74M (−4.2%) |
| Value | $125.4M | $66.3M | −$59.1M (−47.1%) |
New holders (21)
Institutions that held Seres Therapeutics, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Bridgeway Capital Management, LLC | 150,000 | $116.1K | 0.00% |
| Atom Investors LP | 103,316 | $80.0K | 0.01% |
| Catalyst Funds Management Pty Ltd | 95,990 | $74.3K | 0.02% |
| Virtu Financial LLC | 94,510 | $73.0K | 0.01% |
| Prelude Capital Management, LLC | 70,598 | $54.6K | 0.00% |
| Prudential Financial Inc | 22,745 | $17.6K | 0.00% |
| Two Sigma Securities, LLC | 20,874 | $16.2K | 0.00% |
| Wolverine Trading, LLC | 17,969 | $13.9K | 0.00% |
| MML Investors Services, LLC | 14,889 | $12.0K | 0.00% |
| Engineers Gate Manager LP | 12,651 | $9.79K | 0.00% |
| Commonwealth Equity Services, LLC | 11,368 | $9.00K | 0.00% |
| HSBC Holdings PLC | 11,233 | $8.70K | 0.00% |
| Summit Trail Advisors, LLC | 10,000 | $7.74K | 0.00% |
| ICA Group Wealth Management, LLC | 1,600 | $1.24K | 0.00% |
| Continuum Advisory, LLC | 955 | $984 | 0.00% |
| TFC Financial Management | 1,000 | $775 | 0.00% |
| Huntington National Bank | 230 | $178 | 0.00% |
| Nisa Investment Advisors, LLC | 108 | $84 | 0.00% |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 20 | $15 | 0.00% |
| CWM, LLC | 108 | $0 | 0.00% |
| Mirae Asset Global Investments Co., Ltd. | 50,102 | – | – |
Sold out (25)
Institutions that held Seres Therapeutics, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.